Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.

Leuk Lymphoma

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Published: July 2021

Download full-text PDF	Source
http://dx.doi.org/10.1080/10428194.2021.1885654	DOI Listing

Publication Analysis

cladribine cytarabine

cytarabine gcsf

gcsf mitoxantrone

mitoxantrone clag ± m

clag ± m highly

highly effective

effective poor

poor risk

risk acute

acute myeloid

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!